BackAdial Pharmaceuticals- Warrants (31/07/2023) Overview

Adial Pharmaceuticals- Warrants (31/07/2023) Net Tangible Assets

Adial Pharmaceuticals- Warrants (31/07/2023)'s net tangible assets is $-38M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-38.38M
786.45% YoYΔ $-43.97M vs prior year quarter

Peer trimmed avg / median

Loading

Adial Pharmaceuticals- Warrants (31/07/2023) Net Tangible Assets History

Loading

Adial Pharmaceuticals- Warrants (31/07/2023) vs. peers: Net Tangible Assets Comparison

Loading

Adial Pharmaceuticals- Warrants (31/07/2023) Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Adial Pharmaceuticals- Warrants (31/07/2023) (ADILW) FAQ

Adial Pharmaceuticals- Warrants (31/07/2023)'s net tangible assets stands at $-38M as of June 2026. That compares with $5.6M in the prior-year period — down 786.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Adial Pharmaceuticals- Warrants (31/07/2023) reported $-38M in net tangible assets versus $5.6M a year earlier — a 786.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $5.6M in the prior-year period — down 786.4% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Adial Pharmaceuticals- Warrants (31/07/2023)'s net tangible assets evolved across reporting periods, while the comparison chart places ADILW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Adial Pharmaceuticals- Warrants (31/07/2023)'s reading of $-38M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.